Chronic myelogenous leukemia (CML) is caused by the constitutively active Bcr-Abl tyrosine kinase, which can be effectively inhibited by imatinib mesylate (Gleevec, STI571). Imatinib has become the standard treatment for newly diagnosed CML. 1 However, resistance to imatinib due to point mutations in the Bcr-Abl kinase domain is a frequent problem in advanced phase CML therapy. 2, 3 This has led to the development of alternative Abl kinase inhibitors and efforts to combine imatinib with inhibitors of pathways downstream of Bcr-Abl. The serine/threonine kinase m-TOR is believed to be important for Bcr-Abl-mediated leukemogenesis, since m-TOR is activated by the PI3-Kinase/Akt-pathway, which in turn is induced by Bcr-Abl. 4, 5 The m-TOR inhibitors rapamycin (sirolimus) and its derivative RAD001 (everolimus) have been shown to inhibit the growth of a variety of transformed cells including CML-derived cell lines, and it was recently shown that imatinib and rapamycin can act in a synergistic manner on Bcr-Abl expressing cells. 5, 6 However, conflicting data have been reported on the combined effects of imatinib and rapamycin on cells expressing imatinib resistant Bcr-Abl mutations such as Bcr-Abl T315I , a mutation mediating strong imatinib resistance.
2,3
Mohi et al 6 found imatinib and rapamycin to act synergistically both on Bcr-Abl wild type and Bcr-Abl T315I expressing Ba/F3 cells, whereas Ly et al 5 observed increased inhibition of BcrAbl wt cells, but in contrast to the work by Mohi et al 6 resistance to both imatinib and rapamycin in Bcr-Abl T315I cells. We therefore examined the effects of combining imatinib with rapamycin using Bcr-Abl mutations mediating different degrees of imatinib resistance and extended our work to RAD001, a derivative of rapamycin with improved oral bioavailability.
We first examined the effects of rapamycin and its more bioavailable derivative RAD001 on IL-3-dependent parental Ba/F3 cells and Ba/F3 cells transformed with p185 Bcr-Abl wild type (Bcr-Abl WT ). Both cell lines were exposed to escalating doses of rapamycin and RAD001. Rapamycin ( Figure 1a ) and RAD001 ( Figure 1b) inhibited growth of both parental, and wild type Bcr-Abl-positive Ba/F3 cells (Bcr-Abl WT ) with equal effectivity, suggesting that m-TOR inhibitors suppressed cell growth independent of Bcr-Abl expression. At concentrations above 5 nM rapamycin and 3.2 nM RAD001, a plateau of about 60% inhibition was reached.
Next, we used different concentrations of rapamycin or imatinib and combinations thereof to treat Ba/F3 cells expressing Bcr-Abl WT. As expected, in Bcr-Abl WT cells imatinib alone was sufficient to inhibit the cell growth by more than 80% at a concentration of 1 mm (Figure 2a ). Rapamycin alone at 1 nM led to 59% growth inhibition, and a combination of 1 nM rapamycin and 500 nM imatinib increased inhibition to 84% (Figure 2a ). The combination index (CI) values for imatinib and rapamycin for Bcr-Abl WT expressing cells indicated synergistic effects (Figure 2a , lower right), with a CI of 0.55 at 75% growth inhibition (ED 75 ). There have been conflicting data on the effects of imatinib/rapamycin combination treatment of Bcr-Abl mutations that cause strong resistance towards imatinib, such as T315I and E255K. When Ba/F3 cells expressing Bcr-Abl mutants mediating strong imatinib resistance were examined, imatinib alone did not inhibit growth of Bcr-Abl T315I or Bcr-AblE255K cells at concentrations up to 2 mM as expected (Figure 2b and c) . In contrast, rapamycin alone clearly inhibited proliferation of these cells, albeit to the same extent as in cells expressing Bcr-Abl WT or in parental Ba/F3 cells (compare Figures 1a, 2a-c) . Combining rapamycin and imatinib led to inhibition levels that corresponded to those of rapamycin as a single agent (Figure 2b and c). We next examined imatinib and rapamycin on BcrAblF317V expressing cells, a mutant that mediates a moderate resistance to imatinib. 8 In these cells, synergistic growth Spotlight Correspondence inhibition in the presence of various combinations of imatinib and rapamycin could be achieved (Figure 3a , CI ED75 of 0.46). Thus, when m-TOR inhibition is employed together with an Abl kinase inhibitor, synergistic inhibition may require significant activity of the kinase inhibitor when used as a single agent. This hypothesis was further strengthened by the observation of synergistic growth inhibition of Bcr-AblE255K cells, when rapamycin was used in combination with PD166326, an Abl kinase inhibitor which is known to suppress Bcr-AblE255K. 8 As a single agent, both PD166326 (20 nM) or rapamycin (1 nM) led to a growth inhibition of 60 and 61%, respectively (Figure 3b) , their combination however resulted in 85% inhibition. At inhibition levels greater than 60%, synergistic activity could be seen, with a CI ED75 of 0.84 (Figure 3b, lower right) .
Similar results were obtained using the rapamycin derivative RAD001, which was active when used as a single agent, and synergistically active in combination with imatinib in Bcr-Abl Our data suggest that inhibitors of m-TOR, when used in combination with Abl tyrosine kinase inhibitors may increase chances of preventing the emergence of inhibitor resistance. However, synergistic activity of both inhibitor classes was strictly dependent on at least some residual activity of the Abl kinase inhibitor on a particular Bcr-Abl mutant. Mohi et al 6 recently reported single activity of imatinib in Bcr-Abl T315I cells. Consequently, these authors achieved synergistic inhibition using combinations of imatinib and rapamycin in Ba/F3 cells expressing Bcr-Abl T315I . 6 This synergistic effect was not seen in our study or in the study by Ly et al 5 as imatinib reportedly is not capable of suppressing Bcr-Abl T315I . 2, 3 Therefore, combination treatment with imatinib should be most effective in cases where Bcr-Abl mutants cause moderate resistance to imatinib but not in cells harbouring a Bcr-Abl mutant mediating complete resistance to Abl inhibition. In this case, novel Abl kinase inhibitors may be employed in combination with m-TOR inhibitors.
RAD001 displays superior bioavailability after oral administration and showed equal effectivity to rapamycin. RAD001 can therefore be viewed as a reasonable alternative to rapamycin in CML therapy and has already entered clinical trials for imatinib resistant CML patients.
